J Mitra, India’s leading IVD (in-vitro diagnostic) manufacturing company, has launched India’s first portable diagnostic solution – the iQuant immunoassay analyzer in the Indian market.
The latest solution has been launched in collaboration with IIT Madras’ HTIC (Healthcare Technology Innovation Centre).
The portable solution is a state-of-the-art Fluorescence Immunoassay Analyzer for quantitative and qualitative determination of blood test parameter – that includes TSH (Thyroid Stimulating Hormone), T3 (Tri-iodo thyronine), T4 (Thyroxin), Vitamin D, Dengue NS1 Antigen, Dengue IgM, Dengue IgG and HbA1c test.
Beta-testing for the product had been going on for the past eight months. With this launch, various highly-active and sought-after diagnostic solutions will be available across the country and in the remotest of locations at the fraction of a cost.
It will be adding to the number of diagnostic solutions, which will be available as a software upgrade on the cloud.
Responding to the development, Jatin Mahajan, managing director, J Mitra said, “iQuant is an innovative mix – on the product side, it is a mix of science, IT, healthcare and research, while on the implementation side it is great combination of social conditions, ground realities coupled with business sense”. He further added, “This is an innovative, path-breaking product that will greatly influence the detection and diagnostic process, which will hasten the treatment and cure process – resulting in a healthier India, in line with government’s healthcare-for-all initiative.”
This is a home-grown innovative solution – a “completely Made-in-India” offering. While being the most cost-effective solution available in the market today, what sets it apart is the fact that it is completely portable.
It can be carried with ease and has a self-sustaining power supply. It is thus quite suited for Indian conditions, especially for remote and electricity-dark areas.
J Mitra which exports to more than 45 countries across the globe, holds the maximum number of patents (over 55 patents) in the IVD segment for its innovative and research-based solutions.